Nephros Covid-19 Operational Update

Dan D’Agostino – Chief Financial Officer

Daniel-DAagostino-Photo

Dan has 20+ years of executive experience in the medical technology and investment banking industries. Previously, he was head of healthcare at RW Pressprich & Co., a full-service investment bank focused on growth companies in Healthcare, Technology and Aviation sectors. Prior to RWP, Dan was CEO and CFO of AmeriTech Advisors a full-service investment bank focused on growth companies in the Medtech and Tech sectors from 2009-2017. Prior to ATA, Dan was at ThinkEquity Partners as head of the healthcare investment banking and prior to that served as acting Chief Financial Officer and Chief Business Officer of Synergy Pharmaceuticals (Nasdaq: SGYP) a bio-pharmaceutical company focused on GI conditions from 2003 to 2007. Prior to Synergy, Dan was co-head of investment banking at Punk, Ziegel & Company where he was a partner for six years. He was also a mergers and acquisitions banker at Deutsche Bank/ BT Alex.Brown, Wasserstein, Perella & Co. and Credit Suisse. Dan is board member and chairman of the audit committee for SentrX Animal Care. He has closed transactions with bioMerieux SA, Apotex, Inc, Accelerate Dx, ArQule, Synergy Pharmaceuticals, Progenics Pharmaceuticals, Assertio Therapeutics, Cell Therapeutics, EntreMed, Vion, Axonyx, Generac, JF Lehman, Beacon Group and many other strategic and financial groups. His experience includes leading buyside and sellside M&A advisory assignments, IPO’s, public debt and equity financings, senior debt facilities and private placements. Dan earned an MBA in Finance and Masters Degree in International Affairs from Columbia University and a Bachelor of Science in Accounting from Tulane University.